Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10722678 | 0.90 | ACHE (0.82) | ACHEGRM5KMT2ANPC1RAB9A | |
| SCHEMBL433828 | 0.89 | ACHE (0.81) | ACHEGRM5KMT2ANPC1RAB9A | |
| SCHEMBL18166097 | 0.89 | ACHE (0.81) | ACHEGRM5KMT2ANPC1RAB9A | |
| SCHEMBL25946040 | 0.89 | ACHE (0.81) | ACHEGRM5KMT2ANPC1RAB9A | |
| SCHEMBL10724144 | 0.87 | ACHE (0.77) | ACHEGRM5KMT2ANPC1RAB9A | |
| SCHEMBL22628934 | 0.87 | ACHE (0.77) | ACHEGRM5KMT2ANPC1RAB9A | |
| SCHEMBL23440265 | 0.86 | ACHE (0.74) | ACHEGRM5KMT2ANPC1RAB9A | |
| SCHEMBL13931022 | 0.86 | ACHE (0.74) | ACHEGRM5KMT2ANPC1RAB9A | |
| SCHEMBL14632231 | 0.86 | ACHE (0.74) | ACHEGRM5KMT2ANPC1RAB9A | |
| SCHEMBL4003983 | 0.85 | ACHE (0.73) | ACHEGRM5KMT2AEPHX1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724325-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | Codexis, Inc. (US) | 2020-10-21 | — | — | EP | claimed |
| CN-111699250-A | Carboxyesterase polypeptides for amide coupling | 科德克希思公司 | 2020-09-22 | — | — | CN | claimed |
| WO-2019118557-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | CODEXIS, INC. (US) | 2019-06-20 | — | — | WO | claimed |
| US-20190177707-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2019-06-13 | — | — | US | claimed |
| US-12286653-B2 | Carboxyesterase polypeptides for amide coupling | CODEXIS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| CN-111699250-B | Carboxylesterase polypeptides for amide coupling | 科德克希思公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210238565-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-08-05 | — | — | US | disclosed |
| US-20210238565-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-08-05 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| US-5488140-A | ANTICONVULSANTS | CIBA-GEIGY CORPORATION (US) | 1996-01-30 | — | — | US | disclosed |
| EP-0420806-B1 | Phosphonic acids, process for preparation and use as an active pharmaceutical composition | CIBA GEIGY AG (CH) | 1995-07-05 | — | — | EP | disclosed |
| US-5294734-A | 1-phosphato-4-amino-pent-2-enoic acids and derivatives | CIBA-GEIGY CORP. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0447292-A1 | 4-Aminomethyl-piperidine derivatives, their preparation and therapeutic application | SYNTHELABO (FR) | 1991-09-18 | — | — | EP | disclosed |
| EP-0420806-A1 | Phosphonic acids, process for preparation and use as an active pharmaceutical composition | CIBA-GEIGY AG (CH) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | CNR2, CNR1, OPRM1 | ACHE 1552/4885GRM5 584/4885KMT2A 2110/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | ACHE 4575/4885GRM5 3035/4885KMT2A 1973/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | ACHE 4707/4885GRM5 2512/4885KMT2A 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.